Sort   by:  
 Page size 
MetabolomicsTargeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer

Poly(ADP-ribose) polymerase inhibitors (PARPi), such as olaparib, have significantly improved outcomes in ovarian cancer (OC); however, therapy resistance remains a major clinical challenge. Here, we showed that glutamine metabolism was upregulated in PARPi-resistant OC cells and identified the g...

2026-04-08 | MTBLS14072 | MetaboLights
ProteomicsA HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant
Although PARP inhibitors (PARPi) now form part of the standard-of-care for the treatment of homologous recombination defective cancers, de novo and acquired resistance limits their overall effectiveness. Previously, overexpression of the BRCA1-∆11q splice variant has been shown to cause PARPi resist...
ORGANISM(S): Homo sapiens (Human) 
2023-07-18 | PXD040430 | Pride
Brca1 Ovarian cancer Parp Huwe1 Parpi 
ProteomicsPARP Inhibitor Sensitivity in BRCA-Proficient ovarian cancer cells is regulated by the MSH6–CHAF1A axis: 2. ADP-Ribosylation
Ovarian cancer is the leading cause of gynecologic cancer-related deaths, with high-grade serous ovarian cancer (HGSOC) being the most common and lethal subtype. While BRCA1/2 mutations are established biomarkers predicting sensitivity to PARP inhibitors (PARPis), a subset of patients with BRCA-prof...
ORGANISM(S): Homo sapiens (Human) 
2026-08-21 | PXD067891 | Pride
Ovarian cancer Parp inhibitor Adp-ribosylation 
ProteomicsProteomic analysis reveals low dose PARP inhibitor-induced differential protein expression in BRCA1-mutated high-grade serous ovarian cancer cells
To detect the off-target effects of PARP inhibition, a quantitative mass spectrometry-based proteomic analysis was conducted of a BRCA1-mutated HGSOC cell line treated with low doses of two PARPi, Niraparib and Rucaparib.
ORGANISM(S): Homo sapiens (Human) 
2022-04-15 | PXD027177 | Pride
Proteomics Ovarian cancer Mass spectrometry Tandem mass tags (tmt) Parp inhibitor (parpi) 
ProteomicsNASP modulates histone turnover to drive PARP inhibitor resistance
PARP inhibitors (PARPi) present a remarkable advance in the treatment of patients with homologous recombination (HR)-deficient tumors1-3, however resistance remains a challenge due to genomic instability4,5. While most research has focused on the downstream consequences of PARPi exposure to tackle r...
ORGANISM(S): Homo sapiens (Human) 
2025-07-29 | PXD061071 | Pride
Lc-msms Nasp Parp inhibitor Human 
ProteomicsInvestigating Synthetic Lethality and PARP Inhibitor Resistance in Pancreatic Cancer Through Enantiomer Differential Activity
The RAD51-BRCA2 interaction is central to DNA repair through homologous recombination. Emerging evidence indicates RAD51 overexpression and its correlation with chemoresistance in various cancers, suggesting RAD51-BRCA2 inhibition as a compelling avenue for intervention. We previously showed that co...
ORGANISM(S): Homo sapiens (Human) 
2025-05-07 | PXD054120 | Pride
Anticancer drugs  homologous recombination  parp inhibitors  protein-protein small molecule inhibitors  parpi resistance  within-pathway synthetic lethality (wpsl) 
GenomicsNASP modulates histone turnover to drive PARP inhibitor resistance
NASP modulates histone turnover to drive PARP inhibitor resistance
PRJNA1244778 | ENA
GenomicsMapping the Genetic Interaction Network of PARP inhibitor Response
Mapping the Genetic Interaction Network of PARP inhibitor Response
PRJNA1196842 | ENA
ProteomicsTargeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer
Despite objective responses to PARP inhibition and improvements in progression-free survival compared to standard chemotherapy in patients with BRCA-associated triple-negative breast cancer (TNBC), benefits are transitory. Using high dimensional single-cell profiling of human TNBC, here we demonstra...
ORGANISM(S): Homo sapiens (Human) 
2021-03-25 | PXD015804 | Pride
Tam (tumor associated macrophage) Tmt Parp Lumos 
GenomicsNASP modulates histone turnover to drive PARP inhibitor resistance
NASP modulates histone turnover to drive PARP inhibitor resistance
PRJEB86492 | ENA
Sort   by:  
 Page size